The reversible inhibition of calcineurin (CaN), which is the only Ca 2؉ /calmodulin-dependent protein Ser/Thr phosphatase, is thought to be a key functional event for most cyclosporin A (CsA)-and tacrolimus (FK506)-mediated biological effects. In addition to CaN inhibition, however, CsA and FK506 have multiple biochemical effects because of their action in a gain-of-function model that requires prior binding to immunophilic proteins. We screened a small molecule library for direct inhibitors of CaN using CaN-mediated dephosphorylation of 33 P-labeled 19-residue phosphopeptide substrate (RII phosphopeptide) as an assay and found the polyphenolic aldehyde gossypol to be a novel CaN inhibitor. Unlike CsA and FK506, gossypol does not require a matchmaker protein for reversible CaN inhibition with an IC 50 value of 15 M. Gossypolone, a gossypol analog, showed improved inhibition of both RII phosphopeptide and p-nitrophenyl phosphate dephosphorylation with an IC 50 of 9 and 6 M, respectively. In contrast, apogossypol hexaacetate was inactive. Gossypol acts noncompetitively, interfering with the binding site for the cyclophilin 18⅐CsA complex in CaN. In contrast to CsA and FK506, gossypol does not inactivate the peptidyl-prolyl-cis/ trans-isomerase activity of immunophilins. Similar to CsA and FK506, T cell receptor signaling induced by phorbol 12-myristate 13-acetate/ionomycin is inhibited by gossypol in a dose-dependent manner, demonstrated by the inhibition of nuclear factor of activated T cell (NFAT) c1 translocation from the cytosol into the nucleus and suppression of NFAT-luciferase reporter gene activity.
In vivo inhibition by membrane-penetrable low molecular mass compounds plays an important role in evaluating the biological function of enzymes involved in protein phosphorylation/dephosphorylation. The functional discrimination with specific inhibitors of the four major protein Ser/Thr phosphatases, protein phosphatase 1 (PP1), 1 protein phosphatase 2A (PP2A), protein phosphatase 2B (PP2B, calcineurin, CaN), and protein phosphatase 2C (PP2C), has proven to be successful (1) . Okadaic acid and microcystin are strong inhibitors of PP1 and PP2A, but they exhibit poor inhibition of the Ca 2ϩ /calmodulinregulated CaN and PP2C. It was difficult to identify CaN function in cell signaling until the membrane-penetrable cyclopeptide cyclosporin A (CsA) and the peptidomacrolide FK506 were found to inhibit CaN specifically under certain conditions (2) . Currently, most reports about CaN involvement in cellular processes are based on CsA and FK506 susceptibility of the appropriate bioassays. CaN inhibition by these drugs is characterized by their prior binding to the 18-kDa cyclophilin (Cyp18) and 12-kDa FK506-binding protein (FKBP12), respectively, indicating a gain-of-function mechanism (3). These mammalian prototypes of two different families of the enzyme class of peptidyl-prolyl-cis/trans-isomerases (EC 5.2.1.8; PPIases) function as molecular matchmakers because the drugs cannot bind to CaN on their own. The prototypic PPIases are themselves tightly inhibited in the course of formation of the CaN-inhibitory PPIase⅐drug complex (4) .
It is essential to recognize the uncertainties in the interpretation of the biological effects found for the application of CsA and FK506 in cellular assays. They include the above discussed multifunctional biochemical properties released through the PPIase-drug interaction and the often unknown cellular content and isoenzyme composition of the matchmaker proteins. Recent analyses of the human genome revealed the existence of 18 cyclophilins and 16 FKBPs, at least, most of which have the potential to be enzymatically active and to form PPIase⅐drug complexes with mostly unknown affinity for CaN (5) (6) (7) .
In fact, the CaN-inhibitory complexes of different affinity for CaN are formed from the matchmaker proteins in competition for the limiting amounts of the drug rendering inhibition less predictable. Other drug effects may result from the facilitated dissociation of receptor⅐PPIase complexes (8, 9) and the slow rate of formation of the PPIase⅐drug complexes (10, 11) . In addition, the PPIase-mediated intracellular accumulation of the drugs prevents the reliable analysis of dose-response curves. Although the molarity of the administered dose is known, the variable intracellular PPIase concentration does not permit calculation of the biologically effective dose.
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Although the use of drug derivatives lacking the CaN effector domain has permitted the application of CaN-inactive PPIase inhibitors (12) (13) (14) (15) , corresponding experiments with specific small molecule CaN inhibitors, which are inactive toward PPIases, are still missing. The results of biological studies using pyrethroid insecticides as CaN inhibitors (16) were at variance with recent investigations that could not find any CaN inhibition with this class of compounds (17, 18) . The tyrphostin class of tyrosine kinase inhibitors possesses CaN inhibitory potency in the micromolar range but lacks CaN specificity. The CsA-like anti-HIV-1 replication inhibition of ring-substituted benzothiophen-2-carboxamide was attributed to its CaN-inactivating properties (19) . However, CaN inactivation has not been characterized with purified enzyme, and CsA does not act on HIV-1 replication via CaN inhibition (13) .
Irreversible CaN inactivation by 4-(fluoromethyl)phenyl phosphate is active in the millimolar range but does not exhibit CaN specificity (20) . A similar disadvantage must be considered for cantharidin and endothall as CaN inhibitors because they cannot differentiate between CaN and PP1 or PP2A (21, 22) . The inhibition of CaN-mediated dephosphorylation RII phosphopeptide by the dihydroisobenzofuran dibefurin exhibits an IC 50 of 46 M, but the specificity of inhibition remains unknown. Interestingly, this compound was active in the mixed lymphocyte reaction assay (23) .
Alternatively, CaN-inhibitory polypeptides as a 25-residue oligopeptide excised from the autoinhibitory CaN domain (IC 50 ϭ 10 M) (24), the 97-amino acid residue autoinhibitory oligopeptide of CaN (IC 50 ϭ 5 M) (25) , and the AKAP79 protein (IC 50 ϭ 4.2 M) (26) may serve as possible functional probes but have high molecular masses and transport limitations.
To provide a more reliable tool for investigating the role of CaN in cellular processes, we screened a compound library for low molecular mass inhibitors of CaN-mediated dephosphorylation of RII phosphopeptide. The experimental approach is based on a scintillation proximity concept with streptavidincoated scintillation wells. The polyphenolic aldehyde gossypol was identified as a reversible inhibitor that is specific for CaN among the Ser/Thr phosphatases and does not require prior binding to a molecular matchmaker. Furthermore, we have characterized the ability of gossypol to inhibit CaN-mediated cellular dephosphorylation of the cytoplasmic component of the transcription factor NFAT using Western blotting and the NFAT-luciferase reporter gene assay.
EXPERIMENTAL PROCEDURES

Materials
Streptavidin-coated scintillation wells were purchased from Wallac (Turku, Finland). The biotinylated and nonbiotinylated 19-residue peptides of a partial sequence of the subunit of the bovine cAMP-dependent protein kinase (DLDVPIPGRFDRRVSVAAE-OH) were synthesized. The purity of the peptides was assessed by analytical reversed phase high performance liquid chromatography. Peptides were characterized by electrospray ionization-mass spectrometry. Recombinant human Cyp18, human FKBP12, and human Pin1 were prepared as described elsewhere (27, 28) . The catalytic subunit of bovine heart cAMP-dependent protein kinase (protein kinase A) was obtained from Roche (Mannheim, Germany). PP1 (recombinant rabbit muscle ␣-isoform) was purchased from Calbiochem, and PP2C (recombinant human ␣-isoform) was from Upstate Biotechnology. Trimeric PP2A with a subunit composition of C␣/␤ A␣ B␣ was kindly provided by A. Werner (University Halle, Germany). Calmodulin, (ϩ/Ϫ)-gossypol, (ϩ/Ϫ)-gossypolone, (ϩ/ Ϫ)-apogossypol hexaacetate, buffers, and salts were purchased from Sigma. Expression and purification of the recombinant human CaN ␣ (rhCaN) from the Escherichia coli strain BL21-(pLysS)/pETCN␣/ pBB131 was performed as described previously (29) .
The Natural Products Pool compound library (Hans-Knöll-Institute for Natural Products Research, Jena, Germany) at the time comprising ϳ5,000 pure compounds was used (30) .
Enzyme Activity Assays
RII Phosphopeptide-The biotinylated and nonbiotinylated 19-residue peptides of a partial sequence of the subunit of the bovine protein kinase A were phosphorylated according to a procedure described previously (31) . In brief, the reaction mixture contained the following concentrations: 700 M peptide, 100 Ci of [␥- 33 P]ATP with a specific activity of ϳ3,000 Ci/mmol from a stock solution of 10 Ci/l (ICN, Eschwege, Germany), and 125 M ATP in a final volume of 100 l of buffer (20 mM MES, pH 6.5, 0.4 mM EDTA, 0.2 mM EGTA, 50 M CaCl 2 , and 5 mM MgCl 2 ). The phosphorylation of the peptides in the reaction mixture was performed with 10 milliunits of protein kinase A at 30°C for 1 h. Then the peptides and ATP were separated by a 1-ml RP-C2 clean-up extraction column (Amchro, Sulzbach, Germany). The peptides were eluted with 70% acetonitrile and water, then freeze-dried and dissolved in water prior to use. The level of peptide phosphorylation was 24%. The calculation takes into account the total amount of radioactivity in the peptide fraction, the specific activity of incorporated 33 P, and the ratio of radioactive and nonradioactive ATP in the reaction mixture.
RII Phosphopeptide-based CaN Activity Assay-The scintillation proximity concept (32, 33) has been applied to measure CaN activity using scintillation wells coated with streptavidin.
Preincubation of 50 nM calmodulin, 1.32 nM CaN, and inhibitor at the required concentrations in assay buffer (40 mM Tris-HCl, pH 7.5, 100 mM NaCl, 6 mM MgCl 2 , 0.5 mM dithiothreitol, 1 mM CaCl 2 , 0.1 mg/ml bovine serum albumin) was carried out at 22°C for 30 min in a 96-well microtiter plate (Costar, Bodenheim, Germany). 10 pmol of biotinylated 33 P-labeled RII phosphopeptide was added to each well in a total assay volume of 100 l. After dephosphorylation of the modified RII phosphopeptide by CaN at 30°C for 20 min, a 90-l sample of the reaction mixture was transferred to a scintillation well coated with streptavidin. Biotinylated RII phosphopeptide was allowed to bind to streptavidin for 20 min at 22°C. The well was washed once with water, and the RII phosphopeptide-associated 33 P radioactivity was measured in a MicroBeta top counter (Wallac).
Assay of Protein Phosphatases Using
32 P-labeled Protein Substrates-PP1 and PP2A were assayed by using 32 P-labeled phosphorylase a as described by Pelech and Cohen (34) . For CaN and PP2C 32 P-labeled casein was used as substrate (35) . Procedures for 32 P labeling are detailed in Refs. 36 and 37. Phosphorylase b, phosphorylase kinase, and casein were purchased from Sigma.
Inhibition of CaN-Stock solutions of substances from the product library (10 mg/ml dimethyl sulfoxide) tested for CaN inhibition were stored at Ϫ70°C. Each substance was assayed at a final concentration of 100 g/ml in the reaction mixture.
CaN inhibition was measured in a concentration range of 0.5-200 M gossypol and gossypol derivatives at optimal Ca 2ϩ and calmodulin concentrations. The obtained data were fitted and computed with the SigmaPlot program (SPSS Inc., San Rafael, CA).
For competition experiments, the CaN/gossypol mixture was equilibrated in the assay buffer at 22°C for 30 min. Subsequent use of the incubation mixture in the RII phosphopeptide-based CaN assay yielded a final concentration of 1.3 nM CaN and 12 M gossypol. Residual CaN activity was determined in the simultaneous presence of gossypol and 10 M CsA at varying concentrations of rhCyp18 and under similar conditions for CsA and gossypol alone. CaN activity was referenced to the assay lacking additional compounds.
For kinetic analyses, biotinylated 33 P-labeled RII phosphopeptide and nonbiotinylated RII phosphopeptide were mixed at a concentration ratio of 1:200 in the assay buffer. A total RII phosphopeptide concentration of 5-10 M was used for each concentration of gossypol (5-20 M).
p-Nitrophenyl Phosphate (pNPP)-based CaN Activity Assay-Phosphatase activity was measured at room temperature using pNPP as substrate in phosphatase assay buffer (see above). After preincubation of CaN and calmodulin with the inhibitor in the assay buffer at room temperature for 20 min, the reaction was initiated by the addition of pNPP to final concentrations up to 25 mM. The release of p-nitrophenol was measured continuously on a Dynatec MR7000 micotiter plate reader at 410 nm for 30 min.
PPIase Assay-PPIases activity was determined with oligopeptide substrates using protease-coupled assays as described elsewhere (38, 39) . Typically, experiments were performed with the PPIase concentrations in the low nM range and 120 M gossypol within the assay. The effect of gossypol on the PPIase activity was calculated from the re-maining activity after preincubation of the enzyme and the inhibitor for 20 min.
Reversibility of CaN Inhibition
The equilibrated 120 M gossypol and 13.2 nM CaN mixture (stock solution) in assay buffer containing 50 nM calmodulin was used to examine the reversibility of inhibition by dialysis experiments. The mixture was placed on a Pierce system microdialyzer equipped with a M r 3,000 cutoff dialysis membrane and dialyzed against the assay buffer at 4°C. Reference activity was determined with a CaN sample treated similarly but lacking gossypol. Aliquots of 10 l of dialyzed enzyme or gossypol-enzyme complex were assayed using RII phosphopeptide substrate.
Ferrous ammonium sulfate at a final concentration of 50 -500 M was used to study the ability to recover the activity of gossypol-inhibited CaN according to the procedure described previously (40) . CaN activity was assayed using the pNPP substrate.
Elution of CaN from a Cyp18⅐CsA Affinity Column by Gossypol
For preparation of the column, 500 g of rhCyp18 was immobilized on 250 g of Affi-Gel 10 (Bio-Rad). Remaining reactive groups of the gel were blocked by the addition of 1 M Tris-HCl, pH 7.5. Subsequently the column was preincubated with 300 nmol of CsA for 1 h. Before and after binding of 30 g of CaN on the column the beads were washed several times with phosphate-buffered saline. Elution of CaN was performed by incubation for 10 min with 100 M apogossypol hexaacetate, following 100 M gossypol and 15 M preformed Cyp18⅐CsA complex. Eluates were analyzed by Western blotting using in-house rabbit anti-human polyclonal antibodies specific for CaN.
Inhibition of Other Protein Ser/Thr Phosphatases
The activities of the three protein phosphatases PP1, PP2A, and PP2C were measured with RII phosphopeptide, as described for CaN. For assaying PP2C a final concentration of 30 mM MgCl 2 was also included. The protein phosphatase concentrations were adjusted to an activity level of ϳ80% dephosphorylation of 10 pmol RII phosphopeptide within 20 min. Protein phosphatase inhibition was evaluated for gossypol at a concentration range of 1-100 M.
T Cell Purification and Cell Culture
Human peripheral blood mononuclear cells were obtained from healthy volunteers using Ficoll-Hypaque gradient centrifugation. CD4 and CD8 T cells (Ͼ97% pure) were purified by positive selection using magnetic Multisort-MicroBeads (Miltenyi Biotech, Bergisch Gladbach, Germany) according to the manufacturer's instructions.
The selected cells were cultured at 3 ϫ 10 7 /ml in RPMI 1640 (Biochrom, Berlin) supplemented with 10% fetal bovine serum, 2 mM Lglutamine, 100 units/ml penicillin, and 100 g/ml streptomycin overnight. Then, lymphocytes were split and preincubated with one of the following compounds at various concentrations as indicated: CsA (AWD, Dresden, Germany), apogossypol hexaacetate, or gossypol at 37°C for 10 min. Stock solutions of the three compounds in dimethyl sulfoxide (Sigma) were added to a final concentration of 0.5% dimethyl sulfoxide in each cell sample. T cells were then stimulated with 40 nM PMA and 2 M ionomycin at 37°C for 20 min. Cells were lysed immediately in hypotonic lysis buffer (10 mM HEPES, pH 7.5, 0.1 mM EDTA, 10 mM KCl, and 0.625% Nonidet P-40) freshly supplemented with complete protease inhibitor mixture (Roche Molecular Biochemicals) and 1 mM dithiothreitol on ice for 20 min and cleared by centrifugation.
Western Blotting
The proteins were separated in 10% SDS-polyacrylamide gels and transferred onto polyvinylidene difluoride membranes (Schleicher & Schuell). Membranes were probed with monoclonal antibodies against NFATc1 and actin (Santa Cruz Biotechnology, Santa Cruz, CA) or polyclonal antibodies against CaN followed by horseradish peroxidaselabeled secondary antibodies and visualized with the enhanced chemiluminescence reaction (Amersham Pharmacia Biotech).
Luciferase Reporter Gene Assay
Sorted T cells transfected with the NFAT-luciferase reporter plasmid (Stratagene) by electroporation were cultured in RPMI 1640 with 10% fetal calf serum for 16 h at 37°C in 5% CO 2 . The cells were incubated with CsA, gossypol, or apogossypol hexaacetate for 30 min and then stimulated with 40 nM PMA and 2 M ionomycin for 5 h. The level of the extracted luciferase from these cells was determined by bioluminescence measurement using the luciferase assay system (Promega).
RESULTS
CaN Activity Assay-Scintillation wells coated with streptavidin-bound biotinylated 33 P-labeled RII phosphopeptide were used to determine human recombinant CaN activity. About 15 pmol/well biotinylated RII phosphopeptide saturated the binding capacity of the streptavidin wells. All experiments were performed at 10 pmol/well RII phosphopeptide. Fig. 1A shows the amount of dephosphorylated RII phosphopeptide for a constant incubation time at different CaN concentrations. The arrow depicts the CaN concentration of 1.32 nM, which was used in all other experiments. As could be inferred from tion of the scintillation proximity CaN assay is an essential prerequisite for the kinetic evaluation of effective inhibition as found for Cyp23⅐CsA (IC 50 ϭ 50 nM) or FKBP12⅐FK506 (IC 50 ϭ 50 nM) (5). The advantage of this screening assay lies at its high sensitivity by using 33 P-labeled RII phosphopeptide, and thus small amounts of CaN are needed. In contrast to the pNPP assay, colored natural compounds of the pool do not interfere in this test.
Characterization of CaN Inhibition by Gossypol-In the library screened for CaN inhibition the cottonseed oil product gossypol turned out to be the only compound active in the lower micromolar range. Gossypol inhibits CaN with an IC 50 value of 17 Ϯ 1 M with the RII phosphopeptide as a substrate and 14 Ϯ 1 M with pNPP as a substrate. Gossypolone displays a higher inhibitory potency (IC 50 ϭ 9Ϯ1 and 6 Ϯ 1 M, respectively), whereas apogossypol hexaacetate is less active in inhibiting CaN (Fig. 2) . CaN recovery via dialysis from inhibition in the presence of 120 M gossypol was obtained with a final yield of 72% of enzyme activity of a gossypol-free control treated similarly. This finding indicates that inhibition was reversible. After a prolonged preincubation (Ͼ2 h) of gossypolone and CaN, an addition irreversible term of inhibition of about 15% was observed. Therefore, all kinetic experiments have been performed with a preincubation time of 30 min. On the other hand, 500 M ferrous ammonium sulfate did not reverse the degree of CaN inactivation in the presence of 20 M gossypol, indicating that the inhibitor does not act via complexation of divalent metal ions.
The alternative CaN substrate pNPP revealed a similar inhibitory potency for gossypol and, when assayed at different pNPP concentrations, gives the first indication of noncompetitive inhibition (Fig. 3) .
To examine the type of CaN inhibition for peptide dephosphorylation, a series of kinetic experiments with a mixture of 33 P-labeled biotinylated and unlabeled RII phosphopeptides (1:200 concentration ratio) was performed. This mixture exhibits a K m value of 20 Ϯ 3 M when determined by a LineweaverBurk plot (data not shown), which corresponds to the K m of 23 M (41) and 25 M (21) reported for nonbiotinylated RII phosphopeptide under similar reaction conditions. As in the pNPPbased assay, noncompetitive inhibition of CaN by gossypol was seen based on the Dixon plot (Fig. 4) . Because of the complexity of the reaction mixture deviations from the linear behaviors of the plot become visible, which are more prominent in the absence of gossypol. However, the K i value of 17 M estimated from the Dixon plot is similar to the aforementioned IC 50 values of 17 and 14 m (Fig. 2) .
To determine whether or not gossypol and the Cyp18⅐CsA complex share common CaN binding sites, we assayed the residual RII phosphopeptide-dephosphorylating CaN activity at 12 M gossypol in the presence of different concentrations of the Cyp18⅐CsA complex (Fig. 5) . The concentration of the Cyp18⅐CsA complex was assumed to be identical to the Cyp18 concentration in the assay buffer at 10 M CsA because of the high affinity binding of CsA to Cyp18 with a K i value of 2.6 nM (38). The IC 50 value of 270 nM (42) . The simultaneous presence of 12 M gossypol and 10 M CsA at varying Cyp18 concentrations allows the inhibitors to be bound at either identical or independent binding sites (Fig. 5) . Obviously, inhibition increases in the presence of both compounds. However, the magnitude of residual CaN activity is different for both inhibition models where a lower degree of inhibition can be expected for competing binding sites. The feature of the curve shapes based on either the experimental or the calculated data points (Fig. 5) indicates the inhibition model with common drug interaction sites. A close fit of the experimental and the calculated curves (Fig. 5) can be achieved by minor changes of our experimental IC 50 values used for calculating the theoretical curve with this model only.
To test this possibility directly, the Cyp18⅐CsA complex was formed by adding CsA to Affi-Gel-bound Cyp18 (2) followed by elution with various inhibitors. CaN was eluted from the column only by gossypol or Cyp18⅐CsA, but not by apogossypol hexaacetate (Fig. 6) .
The influence of calmodulin on CaN inhibition by gossypol is shown in Fig. 7 . The average IC 50 value was 18 Ϯ 2 M for four different calmodulin concentrations (25-150 nM), indicating that gossypol does not target calmodulin for CaN inhibition.
Specificity of Gossypol-Gossypol was tested as an inhibitor of other protein phosphatases utilizing the biotinylated RII phosphopeptide as a general substrate of protein phosphatases. Despite the lower efficiency relative to CaN, PP2A and PP2C readily dephosphorylate the RII phosphopeptide (43) . In the case of PP1, phosphorylase a was chosen as a substrate because phosphorylated proteins are superior to phosphopeptide substrates regard- ing both specific activity and higher signal-to-noise ratio. Except for CaN, gossypol at up to 100 M concentrations has no inhibitory effect on the other protein phosphatases (Table I) . These results were confirmed by using the protein substrates 32 Plabeled phosphorylase a for PP2A and 32 P-labeled casein for CaN and PP2C (data not shown). To exclude the possibility that in cells gossypol inactivates PPIases, human prototypic members of the three PPIase families were tested at a concentration of 120 M gossypol in PPIase assays. Residual activities of 86% (Cyp18), 92% (FKBP12), and 87% (Pin1) were found.
Inhibition of NFAT Translocation in Activated T Cells-To investigate the effect of gossypol on CaN in cells, we examined the NFATC1 disappearance from the cytosol after PMA/ionomycin activation of T cells. The transcription factor NFAT is present in the cytoplasm of resting T cells and translocates into the nucleus only after dephosphorylation by CaN, which is activated immediately after T cell stimulation with a specific antigen, anti-CD3/CD28 antibodies, or PMA/ionomycin (44) .
Human T cells were purified to 98% from human peripheral blood mononuclear cells by magnetic cell sorting of CD4-or CD8-positive cells. The isolated cells were preincubated with CsA, apogossypol hexaacetate, or gossypol and then stimulated with PMA/ionomycin in the presence of these compounds. The cytosolic portion of NFATc1 is detected in the cytosolic extracts by Western blot analysis. Both CsA and gossypol inhibited NFATc1 disappearance from the cytosol in a concentration-dependent manner (Fig. 8) . In contrast, apogossypol hexaacetate neither inhibited CaN in vitro (Fig. 2) nor prevented NFATc1 disappearance from cytosol after T cell stimulation (Fig. 8) .
The NFAT-luciferase reporter gene assay was used to show that the cytoplasmic disappearance of NFAT after stimulation indeed corresponds to NFAT activation by NFAT dephosphorylation and therefore its nuclear appearance with concomitant DNA binding. It was confirmed by luciferase activity measurement that gossypol and CsA inhibit this NFAT activation, but apogossypol hexaacetate did not (Fig. 9 ).
DISCUSSION
In search for direct small molecule inhibitors of CaN, the naturally occurring polyphenolic aldehyde gossypol (C 30 H 30 O 8 ) was found to inhibit CaN reversibly with a potency in the micromolar range (Fig. 10) . There was no previous evidence for the interaction of gossypol with phosphatases. Furthermore, an approximately 2-fold increase in inhibitory potency was observed for the chinoid metabolic derivative gossypolone compared with gossypol, with an IC 50 value of 7 M. Both CsA and FK506 noncompetitively inhibit CaN with IC 50 values of 270 nM (42) and 57 nM (45), respectively, but each requires the prior binding of a matchmaker protein. Despite the significant homology between the catalytic subunits of the Ser/Thr protein phosphatases, the CaN specificity of the PPIase⅐CsA(FK506) complexes among the four protein phosphatase families is high because the inhibitory complex does not involve the active site (46, 47) . Similarly, gossypol is highly specific for CaN among the Ser/Thr protein phosphatase families including PP1, PP2A, and PP2C as judged by its specific inhibition of CaN at concentrations up to 100 M (Table I) . Unlike CsA and FK506, however, gossypol binds directly to CaN, independent of any matchmaker proteins. The ability of gossypol to inhibit CaN without affecting the enzyme activity of members of the three PPIase families makes it potentially a more specific probe for CaN function than CsA and FK506 for which inhibition of PPIases is a prerequisite for inhibition of CaN.
CaN is a binuclear Fe-Zn metallophosphatase, which is activated by Ca 2ϩ , calmodulin, and bivalent metal ions such as Mn 2ϩ and Ni 2ϩ . The catalytically active form of iron in the active center of CaN is still under debate. It is assumed to be either Fe 2ϩ (40) or Fe 3ϩ (48) . CaN has been reported to be inactivated by oxidative processes and can be reactivated by ferrous ammonium sulfate (40) , dithiothreitol, or the dithiol oxidoreductase thioredoxin (49) . Current hypotheses assume that either the binuclear metal center (40) or modification of cysteine residues (49) can be the target for the oxidative inactivation of CaN. From our experiments, we conclude that gos- sypol does not inactivate CaN by a redox mechanism because (i) high concentrations of dithiothreitol (5 mM) did not prevent inactivation; (ii) ferrous ammonium sulfate failed to reverse the inactivation; and (iii) dialysis recovered a major part of CaN activity. In contrast, gossypol in the micromolar concentration range inactivates sperm adenylate cyclase by chelating the essential metal ion of the enzyme. High manganese concentration protects this enzyme from inactivation. Gossypol inhibits CaN independently of the nature of the three substrates used here. This finding is in contrast with the effect of the Cyp18⅐CsA (FKBP12⅐FK506) complexes, which inhibit the dephosphorylation of the RII phosphopeptide but activate the phosphatase activity of CaN toward a small substrate pNPP by 2-3-fold (2, 5) .
Like Cyp18⅐CsA (31), gossypol inhibits CaN noncompetitively, raising the possibility that it may bind to a site overlapping that for Cyp18⅐CsA. In fact, the competition experiment (Fig. 5) implies that both complexes might exhibit similarity in the way these inhibitors block CaN-catalyzed dephosphorylation. The specific elution by gossypol of CaN from a matrixbound ternary complex Cyp18⅐CsA⅐CaN (Fig. 6 ) supports this inhibition model. The structure of the CaN⅐Cyp18⅐CsA complex has not been published so far but may relate to the ternary inhibitory complex of FK506 (47) . Here, the CaN-interacting parts of the binary FKBP12⅐FK506 complex are remote to the active site of the phosphatase. Because the active sites of CaN, PP1, PP2A, and PP2C display considerable similarities, inhibitory specificity requires inhibitor binding at remote sites. Accordingly, the observed specificity of gossypol among the protein phosphatases is in accordance with the noncompetitive type of inhibition. Active site-directed CaN inhibitors like microcystin or the mixed type inhibitor okadaic acid do not show CaN specificity among the protein phosphatases (31) .
Because the use of pNPP substrate in the CaN assay revealed gossypol to inhibit CaN with IC 50 ϭ 14 Ϯ 1 M, which is similar to the IC 50 value with the RII phosphopeptide as a substrate, a binding regime closer to the active site is implied, but specificity is still retained.
In addition to pNPP and the RII phosphopeptide, we also examined the effect of gossypol and analogs on the dephosphorylation of a protein substrate in vivo. Thus, the CaN-dependent activation of the transcription factor NFAT was investigated in the presence of gossypol and apogossypol hexaacetate in human peripheral blood mononuclear cells. Gossypol is advantageous over peptidic inhibitors (25, 26) for cellular experiments because it is cell-permeable (50). In our assay, the phosphoprotein NFATc1 migrating with an apparent molecular mass of 90 -115 kDa in SDS-polyacrylamide gels serves as the CaN substrate. It was shown previously that the Cyp18⅐CsA (or FKBP12⅐FK506) complex-mediated inhibition of dephosphorylation of NFAT is responsible for the inhibition of interleukin-2 transcription and thus T cell proliferation (46, 51) . Gossypol, but not apogossypol hexaacetate, prevented the dephosphorylation and nuclear translocation of NFATc1 by CaN in a concentration-dependent manner. This effect is similar to that observed for the Cyp18⅐CsA complex observed previously (51) (Fig. 8) . The NFAT-luciferase reporter gene assay was used to show that the cytoplasmic disappearance of NFAT after stimulation indeed corresponds to NFAT activation by NFAT dephosphorylation and therefore its nuclear appearance with concomitant DNA binding and gene transcription. It was confirmed by luciferase activity measurement that gossypol and CsA inhibit the NFAT activation, but apogossypol hexaacetate did not (Fig. 9) .
Inhibition of CaN by gossypol was found to be independent of CaN activation by calmodulin, suggesting that neither cofactor requirement nor calmodulin binding site competition was characteristic of gossypol-mediated inhibition even though gossypol was also reported to bind to calmodulin at an independent site (52) .
The discovery of gossypol as a specific CaN inhibitor is also expected to shed light on how this compound plays the well known role in male antifertilization, inhibition of proliferation of tumor cells, and how it mediates side effects of the contraceptive therapy (53) (54) (55) (56) . Gossypol has already been reported to inactivate intracellular dehydrogenases, protein kinases, steroidogenic adrenal enzymes, cathepsin L, and topoisomerase II. the N-terminal group results in the inactivation of phospholipase A 2 (58) . Typically, gossypol concentrations ranging from 10 to 20 M were antiproliferative in cancer cell lines (60) , irreversibly blocking cells in S phase. Spermicidial activity and alteration in morphology of carcinoma cells can also be found with gossypolone, although it is less efficient than gossypol (60, 61) and therefore suggest a CaN-independent pathway. Yet there exist few studies that examine the impact of gossypol on protein phosphorylation. Treatment of human cancer cell lines with gossypol decreased the ratio of phosphorylated to unphosphorylated cell cycle regulatory retinoblastoma protein at inhibitor concentrations compatible with CaN inhibition, but this suggests a protein kinase as a putative gossypol target (62) . On the other hand, it is interesting to note that the increase in the activity of ornithine decarboxylase, and subsequent proliferation following prolactin stimulation of Nb 2 rat lymphoma cells, can be blocked with both CsA and gossypol (63) .
In conclusion, the novel protein Ser/Thr phosphatase inhibitor gossypol, which is specific for CaN among different members of the phosphatase superfamily, allows CsA(FK506)-mediated CaN and PPIase effects to be differentiated. Previous attempts to distinguish among the enzymes were limited to monofunctional PPIase inhibitors that have no effect on CaN. Now the possibility has been extended to a monofunctional CaN inhibitor that does not require the mediation of any PPIases.
Our experiments with gossypol derivatives showed that gossypol may serve as a lead for the development of specific and potent CaN inhibitors active in the nanomolar range and with improved specificity for CaN while discriminating against other gossypol-sensitive enzymes.
